Sign in Subscribe
Securities law

Alto Neuroscience Class Action Investigation: Lead Plaintiff Deadline Set for September 19, 2025

Strategic Insights

— 1 min read

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the "Company") and reminds investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Alto's treatment for Major Depressive Disorder (MDD) was less effective than claimed.

Key Takeaways:

  • The class action lawsuit was filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) for allegedly making false and/or misleading statements and/or failing to disclose the effectiveness of its treatment for Major Depressive Disorder (MDD).
  • The complaint alleges that Alto's treatment, ALTO-100, was less effective in treating MDD than claimed, and that the Company's business and financial prospects were overstated as a result.
  • The Company issued a press release on October 22, 2024, announcing topline results from the Phase 2b trial evaluating ALTO-100, which stated that the treatment did not meet its primary endpoint.
  • Following the announcement, Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • Analysts, including Jeffries, cut their price targets for Alto's stock and questioned the Company's overall biomarker approach to CNS disorders and psychiatry.
  • The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who directs and oversees the litigation on behalf of the putative class.
  • Members of the putative class may move to serve as lead plaintiff through counsel of their choice, or choose to do nothing and remain an absent class member.

Statistics:

  • Alto's stock price fell 69.99% to $4.36 per share on October 23, 2024.
  • The price drop was a result of the Company announcing that ALTO-100 did not meet its primary endpoint in treating MDD.
  • $10.17 per share is the amount by which Alto's stock price fell after the announcement.
  • Alto has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • The class action lawsuit was filed on or about February 2, 2024 (the "IPO" or "Offering"), in connection with the Company's initial public offering.

Sources:

  • Faruqi & Faruqi, LLP
  • Newsfile Corp.
  • NYSE: ANRO
  • www.faruqilaw.com
  • https://www.newsfilecorp.com/release/262888

Read more